This panel will explore the implications of implementing Project Optimus within early-stage oncology drug development. Discussion will focus on whether the initiative facilitates development acceleration through optimized dose selection, or whether it introduces potential delays in achieving key decision points.
Panelists will include representatives from the biotech sector, mid-sized pharmaceutical companies, a regulatory affairs expert, and a clinical oncologist specializing in early-phase oncology trials. Attendees will gain insights from diverse stakeholder perspectives and real-world experiences in applying Project Optimus principles across different oncology assets.
May 6, 09:00-09:45, room Marriott 1+2
| Name | Position | Institution |
|---|---|---|
| Jozsef Palatka | VP, Medical Director | Syneos Health |
| Name | Position | Institution |
|---|---|---|
| Zohra Lomri | Executive Director, Regulatory Affairs | Syneos Health |
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
